Cutaneous melanoma: a contemporary overview published in The Lancet
A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.
A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.
This prestigious award from the 'Society for Melanoma Research' recognises the contribution Richard has made to global melanoma research over the course of his career.
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.
Read more about how the MIA team continues to play a leading role in pushing melanoma research boundaries at ASCO23, the world's leading clinical oncology conference.
Read more about why Prof Richard Scolyer AO received the IAP Distinguished Pathologist Medal and watch his inspiring acceptance speech.
This is the highest award from the American Society of Dermatopathology, and recognises Prof Scolyer's significant contribution to the field of #dermatopathology.
Combined immunotherapy ipilimumab and nivolumab is now available on the PBS for all advanced melanoma patients.
In a world-first, an early phase trial of an mRNA personalised cancer vaccine has shown promising results for preventing melanoma recurrence in patients with resected high-risk melanoma (stage III and IV).
Read more about the five MIA researchers named on the Clarivate list of Highly Cited Researchers 2022.
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.